The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily

HIV Med. 2005 May;6(3):151-4. doi: 10.1111/j.1468-1293.2005.00279.x.

Abstract

Tenofovir (TDF) co-administered with didanosine (ddI) 400 mg increases ddI plasma concentrations by up to 60%, raising concerns over toxicity. To limit this interaction, the dosage of ddI may be reduced to 250 mg once daily when co-prescribed with TDF. In this clinical cohort, highly active antiretroviral therapy regimens containing TDF and ddI 250 mg were significantly better tolerated than combinations with TDF and ddI at a dose of 400 mg. Low-dose ddI 250 mg once daily plus TDF as part of antiretroviral therapy was effective.

Publication types

  • Comparative Study

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • Didanosine / administration & dosage*
  • Didanosine / therapeutic use
  • Drug Administration Schedule
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / mortality
  • HIV-1*
  • Humans
  • Organophosphonates / therapeutic use*
  • Retrospective Studies
  • Survival Rate
  • Tenofovir
  • Treatment Failure
  • Viral Load

Substances

  • Anti-HIV Agents
  • Organophosphonates
  • Tenofovir
  • Adenine
  • Didanosine